Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.49 |
| ▸ | GRK2 | P25098 | 2/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186903 | 0.88 | PPARA (0.59) | HDAC8HDAC11PPARA | |
| SCHEMBL11936085 | 0.83 | NAMPT (0.46) | HDAC8HDAC11FFAR1PPARAROCK2 | |
| SCHEMBL10294809 | 0.82 | NPSR1 (0.54) | ROCK2 | |
| SCHEMBL11935296 | 0.81 | NAMPT (0.44) | HDAC8HDAC11FFAR1PPARAROCK2 | |
| SCHEMBL2185809 | 0.81 | FFAR1 (0.70) | HDAC8HDAC6FFAR1PPARAHIF1A | |
| SCHEMBL27845742 | 0.78 | HDAC8 (0.58) | HDAC8HDAC6HDAC11FFAR1PPARA | |
| SCHEMBL13702145 | 0.78 | HDAC1 (0.66) | HDAC8HDAC6PTGESROCK2 | |
| SCHEMBL10106419 | 0.78 | MAPT (0.65) | HDAC8HDAC11HIF1A | |
| SCHEMBL2188031 | 0.77 | HIF1A (0.50) | HDAC8HDAC6FFAR1PPARAHIF1A | |
| SCHEMBL2188257 | 0.77 | HIF1A (0.50) | HDAC8HDAC6FFAR1PPARAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342177-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-9447033-B2 | Potassium channel blockers | JAPAN TOBACCO INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20150259282-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-8673901-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2014-03-18 | — | — | US | disclosed |
| EP-2342177-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | Xention Limited (GB) | 2011-07-13 | — | — | EP | disclosed |
| US-20100087428-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| WO-2010023448-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087428-A1 | Novel Potassium Channel Blockers | HCN4, SCN2B, KCNH2 | HDAC8 770/4885HDAC6 1036/4885HDAC11 733/4885 |
| US-20150259282-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | HDAC8 1704/4885HDAC6 1117/4885HDAC11 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.